Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio
March 10, 2021Research and Development Maverick, Takeda, cancer treatment
Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …
Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate
March 10, 2021Research and Development Alzheimer's, Cassava Sciences, Evonik
Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …
Affinivax receives $22m funding for development of Staphylococcus aureus vaccine
March 10, 2021Research and Development Affinivax, bacteria, vaccines
Affinivax has received an award of $22 million funding from CARB-X, a global non-profit organisation, to develop a vaccine targeting Staphylococcus …
CytoDyn’s COVID-19 treatment shows positive results in Phase III trial
March 9, 2021Manufacturing and Production cytodyn, phase 3 trial, vyrologix
Biotechnology company CytoDyn has shown positive results in its Phase III CD12 trial of Vyrologix, its treatment for COVID-19 patients …
FDA approves Kite’s Yescarta therapy for follicular lymphoma
March 9, 2021Manufacturing and Production FDA, Kite, Yescarta
The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …
Camallergy awarded £1.1m government funding for peanut allergy immunotherapy
March 9, 2021Manufacturing and Production Camallergy, UK, allergy
Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …
Valo and ImmunoScape collaboration identifies immunogenic peptides for pan-coronavirus vaccine
March 9, 2021Manufacturing and Production COVID-19, Valo Therapeutics, immunoscape, vaccines
Immunotherapy platform developer Valo Therapeutics has successfully completed a collaboration with the biotechnology company ImmunoScape to identify immunogenic peptides for …
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
CHMP recommends Lilly’s bamlanivimab for COVID-19 patients
March 8, 2021Sales and Marketing COVID-19, EMA, Eli Lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …
FDA grants Priority Review to Korsuva for CKD-associated pruritis
March 8, 2021Sales and Marketing Cara Therapeutics, FDA, Korsuva
The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …
NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies
March 8, 2021Sales and Marketing NICE, spinal muscular atrophy
NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …
ViiV presents positive long-term data for combined HIV treatment
March 8, 2021Sales and Marketing HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
Pharmafile.com’s top 10 news stories of the week
March 5, 2021Medical Communications COVID, COVID-19, COVID-19 vaccine, news roundup, pharma news, roundup
The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% …
FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease
March 5, 2021Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …
Amgen to acquire Five Prime Therapeutics for approximately $1.9bn
March 5, 2021Medical Communications Amgen, Cancer, five prime
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …
Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine
March 5, 2021Medical Communications COVID-19, CureVac, Novartis, vaccines
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …
UK government invests £5m in COVID-19 mRNA vaccine library
March 5, 2021Medical Communications COVID-19, CPI, government, vaccines
The Centre for Process Innovation (CPI) has received a £5 million investment from the UK government, to support the development …
Takeda agree $856m deal with Ovid to take over soticlestat development
March 4, 2021Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat
Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …
Beyond Batten Disease Foundation partners with Actelion on development of combination treatment
March 4, 2021Actelion, Batten disease, Janssen
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
